Endologix, Inc. (NASDAQ:ELGX) fell 1.5% on Thursday . The stock traded as low as $0.68 and last traded at $0.67. 19,264 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,032,123 shares. The stock had previously closed at $0.68.
Several research firms have recently weighed in on ELGX. Oppenheimer reaffirmed a “hold” rating on shares of Endologix in a report on Wednesday, October 3rd. Piper Jaffray Companies lowered shares of Endologix from an “overweight” rating to a “neutral” rating in a report on Friday, August 10th. BMO Capital Markets reaffirmed a “hold” rating and issued a $4.00 target price (down previously from $6.50) on shares of Endologix in a report on Friday, August 10th. BTIG Research reaffirmed a “buy” rating on shares of Endologix in a report on Sunday, November 4th. Finally, Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating and set a $1.50 target price on the stock in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. Endologix presently has a consensus rating of “Hold” and an average price target of $3.08.
The company has a debt-to-equity ratio of 4.38, a quick ratio of 0.96 and a current ratio of 1.55.
A number of large investors have recently modified their holdings of ELGX. Panagora Asset Management Inc. bought a new stake in Endologix during the 3rd quarter worth about $1,223,000. BlackRock Inc. grew its holdings in Endologix by 11.1% during the 2nd quarter. BlackRock Inc. now owns 5,644,438 shares of the medical instruments supplier’s stock worth $31,948,000 after acquiring an additional 565,175 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Endologix during the 3rd quarter worth about $340,000. Marshall Wace LLP bought a new stake in Endologix during the 3rd quarter worth about $238,000. Finally, Paloma Partners Management Co bought a new stake in Endologix during the 3rd quarter worth about $184,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Endologix (ELGX) Trading Down 1.5%” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/12/08/endologix-elgx-trading-down-1-5/3064240.html.
About Endologix (NASDAQ:ELGX)
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
See Also: How dollar cost averaging works
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.